Table 10 Univariate comparison of the patients treated for (gastro)esophageal adenocarcinoma with neoadjuvant CRT vs. definitive CRT
Oncological endpoints | Neoadjuvant CRT (n = 33 patients) | Definitive CRT (n = 33 patients) | p—value |
|---|---|---|---|
LRC | |||
at 1 year in % (95% CI) | 88.2 (76.6–100) | 78.5 (64.6–95.4) | |
at 2 years in % (95% CI) | 83.8 (70.4–99.8) | 65.3 (49.1–86.9) | |
at 5 years in % (95% CI) | 73.4 (53.6–100) | 59.9 (42.9–83.5) | 0.2 |
PFS | |||
at 1 year in % (95% CI) | 71.6 (56.7–90.5) | 67.7 (53.1 – 86.4) | |
at 2 years in % (95% CI) | 59.6 (43.6–81.6) | 47.8 (33.0 – 69.3) | |
at 5 years in % (95% CI) | 43.3 (26.7–70.3) | 17.0 (7.3 – 39.9) | 0.1 |
DMFS | |||
at 1 year in % (95% CI) | 71.6 (56.7–90.5) | 71.4 (57.2 – 89.1) | |
at 2 years in % (95% CI) | 63.4 (47.4–84.6) | 54.7 (39.6 – 75.5) | |
at 5 years in % (95% CI) | 46.1 (28.8–73.6) | 16.9 (7.2 – 39.8) | 0.1 |
OS | |||
at 1 year in % (95% CI) | 89.8 (79.4–100) | 72.3 (58.4 – 89.5) | |
at 2 years in % (95% CI) | 69.0 (53.1–89.8) | 56.1 (41.2 – 76.4) | |
at 5 years in % (95% CI) | 45.1 (27.1–75.1) | 17.8 (7.7 – 41.3) | 0.06 |